Premium
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors
Author(s) -
Nishida Yoshihiro,
Urakawa Hiroshi,
Nakayama Robert,
Kobayashi Eisuke,
Ozaki Toshifumi,
Ae Keisuke,
Matsumoto Yoshihiro,
Tsuchiya Hiroyuki,
Goto Takahiro,
Hiraga Hiroaki,
Naka Norifumi,
Takahashi Shunji,
Ando Yuichi,
Ando Masahiko,
Kuwatsuka Yachiyo,
Hamada Shunsuke,
Ueda Takafumi,
Kawai Akira
Publication year - 2020
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.33201
Subject(s) - pazopanib , medicine , clinical endpoint , response evaluation criteria in solid tumors , neutropenia , adverse effect , clinical trial , oncology , surgery , phases of clinical research , chemotherapy , cancer , sunitinib
Malignant peripheral nerve sheath tumor (MPNST) often does not respond well to chemotherapy and develops against a background of NF1. The purpose of our study was to examine the efficacy of pazopanib against MPNST. Our study was designed as a physician‐initiated phase II clinical trial in patients with advanced MPNST. Patients were registered from 11 large hospitals. The primary endpoint was set to clarify the clinical benefit rate (CBR) at 12 weeks according to response evaluation criteria in solid tumors (RECIST). Progression‐free survival (PFS), overall survival (OS) and the CBR based on modified Choi evaluation at week 12 were set as secondary endpoints along with treatment‐related safety. The study enrolled 12 patients. Median age was 49 years. Seven had Grade 2 and five Grade 3 according to the FNCLCC evaluation. Median follow‐up period was 10.6 months. CBR at 12 weeks was both 50.0% (RECIST and Choi). The median PFS was 5.4 months for both RECIST and Choi, and the median OS was 10.6 months. Of special interest, the median PFS was 2.9 months for patients with FNCLCC Grade 2 and 10.2 months for Grade 3 (both RECIST and Choi). Grade 4 adverse events of neutropenia and lipase elevation were noted in one patient each. The results of this pazopanib therapy were generally better than those of any of the other single molecular targeted therapies reported previously. Although accumulation of more cases remains necessary, we conclude pazopanib treatment for MPNST to be a safe and promising treatment after doxorubicin‐based chemotherapy.